Kevin Feeley Sells 402 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 402 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total value of $36,200.10. Following the transaction, the chief financial officer now directly owns 5,044 shares in the company, valued at $454,212.20. The trade was a 7.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Stock Performance

Shares of WGS opened at $90.79 on Wednesday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The business has a 50-day simple moving average of $84.57 and a two-hundred day simple moving average of $70.78. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -46.32 and a beta of 1.91. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. On average, analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. acquired a new position in GeneDx during the 3rd quarter valued at about $604,000. GSA Capital Partners LLP acquired a new position in GeneDx during the 3rd quarter valued at about $322,000. Royce & Associates LP acquired a new position in GeneDx during the 3rd quarter valued at about $1,201,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in GeneDx during the 3rd quarter valued at about $2,547,000. Finally, Charles Schwab Investment Management Inc. increased its position in GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after buying an additional 110,666 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on WGS shares. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.